This formalin inactivating whole virus particles combined with an alum adjuvant is in phase I/II of development



Syracuse University

- NCT04383574 by Sinovac
- ChiCTR2000032459 by the Beijing Institute of Biological Products, Sinopharm
- ChiCTR2000031809 by the Wuhan Institute of Biological Products, Sinopharm
- Inactivated vaccine by the Institute of Medical Biology, Chinese Academy of Medical Sciences

Inactivated vaccines in clinical trial for SARS-CoV-2

Shin, M.D., Shukla, S., Chung, Y.H. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020). doi: 10.1038/s41565-020-0737-y

https://doi.org/10.1038/s41565-020-0737-y

COVID-19 vaccine development and a potential
nanomaterial path forward

NCT04383574 by Sinovac

This inactivated vaccine of SARS-Cov-2 is currently in phase I/II

ChiCTR2000032459

ChiCTR2000031809

This inactivated vaccine of SARS-Cov-2 is currently in phase I

Learn Before

Related